[go: up one dir, main page]

NO20050294L - Nye forbindelser nyttige i behandlingen av fedme, type II diabetes og CNS forstyrrelser - Google Patents

Nye forbindelser nyttige i behandlingen av fedme, type II diabetes og CNS forstyrrelser

Info

Publication number
NO20050294L
NO20050294L NO20050294A NO20050294A NO20050294L NO 20050294 L NO20050294 L NO 20050294L NO 20050294 A NO20050294 A NO 20050294A NO 20050294 A NO20050294 A NO 20050294A NO 20050294 L NO20050294 L NO 20050294L
Authority
NO
Norway
Prior art keywords
obesity
diabetes
treatment
type
cns disorders
Prior art date
Application number
NO20050294A
Other languages
English (en)
Inventor
Gary Johansson
Annika Jenmalm-Jensen
Katarina Beierlein
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0201925A external-priority patent/SE0201925D0/xx
Priority claimed from SE0202181A external-priority patent/SE0202181D0/xx
Priority claimed from SE0202908A external-priority patent/SE0202908D0/xx
Priority claimed from SE0300357A external-priority patent/SE0300357D0/xx
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Publication of NO20050294L publication Critical patent/NO20050294L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Foreliggende oppfinnelse angår oppfinnelser med generell formel (1), hvori P er sulfon eller sulfonamid; og A, B, W, X, Y og R 3 er som definert i beskrivelsen; farmasøytiske sammensetninger innbefattende disse forbindelsene og anvendelsen av sammensetningene for profylakse og behandling av medisinske tilstander relatert til fedme, type II diabetes og/eller CNS-forstyrrelser, for å oppnå reduksjon av kroppsvekt og kroppsvektøkning.
NO20050294A 2002-06-20 2005-01-19 Nye forbindelser nyttige i behandlingen av fedme, type II diabetes og CNS forstyrrelser NO20050294L (no)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
SE0201925A SE0201925D0 (sv) 2002-06-20 2002-06-20 New compounds
SE0202181A SE0202181D0 (sv) 2002-07-11 2002-07-11 New compounds
US40612002P 2002-08-26 2002-08-26
SE0202908A SE0202908D0 (sv) 2002-10-01 2002-10-01 New compounds
US43401002P 2002-12-17 2002-12-17
SE0300357A SE0300357D0 (sv) 2003-02-10 2003-02-10 New compounds
US46470103P 2003-04-23 2003-04-23
PCT/SE2003/001061 WO2004000828A1 (en) 2002-06-20 2003-06-19 New compounds useful for the treatment of obesity, type ii diabetes and cns disorders

Publications (1)

Publication Number Publication Date
NO20050294L true NO20050294L (no) 2005-02-04

Family

ID=30004107

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050294A NO20050294L (no) 2002-06-20 2005-01-19 Nye forbindelser nyttige i behandlingen av fedme, type II diabetes og CNS forstyrrelser

Country Status (13)

Country Link
EP (1) EP1513828A1 (no)
CN (1) CN1662521A (no)
AU (1) AU2003243091A1 (no)
BR (1) BR0311952A (no)
CA (1) CA2486989A1 (no)
EA (2) EA008835B1 (no)
IL (1) IL165051A0 (no)
MX (1) MXPA04012914A (no)
NO (1) NO20050294L (no)
NZ (3) NZ536600A (no)
RS (1) RS111204A (no)
SG (1) SG156524A1 (no)
WO (1) WO2004000828A1 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1956004B1 (en) 2002-03-27 2012-06-13 Glaxo Group Limited Quinoline derivatives and their use as 5-HT6 ligands
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
AU2004261582C1 (en) 2003-07-22 2010-01-07 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
SE0302760D0 (sv) * 2003-10-20 2003-10-20 Biovitrum Ab New compounds
SE0303480D0 (sv) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
WO2005058858A1 (en) * 2003-12-19 2005-06-30 Biovitrum Ab Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder
GB0407025D0 (en) * 2004-03-29 2004-04-28 Glaxo Group Ltd Novel compounds
US7745436B2 (en) * 2004-04-13 2010-06-29 Synta Pharmaceuticals Corporation Disalt inhibitors of IL-12 production
WO2006062481A1 (en) * 2004-12-09 2006-06-15 Biovitrum Ab New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
AR054044A1 (es) * 2005-05-23 2007-05-30 Astrazeneca Ab Derivados de cromano y tetrahidronaftaleno como moduladores del receptor 5 - ht6; intermediarios en su preparacion; composiciones farmaceuticas que los contienen y su empelo en la fabricacion de medicamentos para el tratamiento de enfermedades del snc y de la obesidad.
US7582767B2 (en) * 2005-06-17 2009-09-01 Biovitrum Ab (Publ.) Substituted sulphonamide compound and uses thereof
WO2007003961A2 (en) * 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
EP2364974A1 (en) 2005-10-07 2011-09-14 Exelixis, Inc. N-(3-Phenylamino-quinoxalin-2-yl)-benzenesulfonamide derivatives as phosphatidylinositol 3-kinase inhibitors
BRPI0618206A2 (pt) 2005-11-03 2011-08-23 Hoffmann La Roche arilsulfonil cromanos como inibidores de 5-ht6, bem como composição farmacêutica, uso e processo para produção dos mesmos
TW200736227A (en) 2005-12-23 2007-10-01 Astrazeneca Ab New compounds III
WO2007147763A1 (en) 2006-06-20 2007-12-27 F. Hoffmann-La Roche Ag Arylsulfonyl naphthalene derivatives and uses thereof
EP2076489A1 (en) 2006-06-20 2009-07-08 F. Hoffmann-Roche AG Arylsulfonamidyl tetralin derivatives and uses thereof
CA2653758A1 (en) 2006-06-20 2007-12-27 F. Hoffmann-La Roche Ag Tetralin and indane derivatives and uses thereof
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US7888662B2 (en) 2008-06-20 2011-02-15 Varian Semiconductor Equipment Associates, Inc. Ion source cleaning method and apparatus
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
AR082889A1 (es) * 2011-05-09 2013-01-16 Forma Therapeutics Inc Compuestos y composiciones para la inhibicion de nampt
EP3083588B1 (en) 2013-12-20 2020-12-09 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
EP3307260A4 (en) 2015-06-12 2019-02-13 Axovant Sciences GmbH DIARYL AND ARYLHETEROARYL UREA DERIVATIVES FOR PROPHYLAXIS AND TREATMENT OF SLEEP BEHAVIORAL DISORDERS IN THE REM PHASE
CA2992518A1 (en) 2015-07-15 2017-01-19 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB947606A (en) * 1961-04-10 1964-01-22 Ici Ltd N-substituted piperazines
US4808595A (en) * 1986-12-24 1989-02-28 Merck & Co., Inc. Furopyridine sulfonamides and their opthalmological compositions
WO1994021619A1 (en) * 1993-03-16 1994-09-29 Pfizer Inc. Naphthalene derivatives
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9904995D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
AU1542201A (en) * 1999-11-05 2001-05-14 Nps Allelix Corp. Compounds having 5-HT6 receptor antagonist activity
GB9926302D0 (en) * 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
CA2408156A1 (en) * 2000-05-05 2001-11-15 Millennium Pharmaceuticals, Inc. Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
CA2412462A1 (en) * 2000-06-14 2001-12-20 Warner-Lambert Company 6,5-fused bicyclic heterocycles
WO2002032863A1 (en) * 2000-10-20 2002-04-25 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
IL158593A0 (en) * 2001-05-11 2004-05-12 Biovitrum Ab Novel, arylsulfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
CA2449874C (en) * 2001-06-07 2009-06-23 F. Hoffmann-La Roche Ag New indole derivatives with 5-ht6 receptor affinity
AU2002309435B2 (en) * 2001-06-11 2008-08-14 Biovitrum Ab (Publ) Substituted sulfonamide compounds, process for their use as medicament for the treatment of CNS disorders, obesity and type II diabetes

Also Published As

Publication number Publication date
EA011581B1 (ru) 2009-04-28
RS111204A (en) 2006-12-15
NZ552283A (en) 2008-07-31
EA200600975A1 (ru) 2006-10-27
SG156524A1 (en) 2009-11-26
CA2486989A1 (en) 2003-12-31
CN1662521A (zh) 2005-08-31
IL165051A0 (en) 2005-12-18
WO2004000828A1 (en) 2003-12-31
EA008835B1 (ru) 2007-08-31
NZ552282A (en) 2008-07-31
EA200500054A1 (ru) 2005-06-30
MXPA04012914A (es) 2005-03-31
AU2003243091A1 (en) 2004-01-06
EP1513828A1 (en) 2005-03-16
BR0311952A (pt) 2005-04-19
NZ536600A (en) 2007-08-31

Similar Documents

Publication Publication Date Title
NO20050294L (no) Nye forbindelser nyttige i behandlingen av fedme, type II diabetes og CNS forstyrrelser
NO20075781L (no) Diarylsulfone-sulfonamider og deres anvendelse
NO20063761L (no) Sulfonamidderivater for behandling av sykdommer
SE0403006D0 (sv) New compounds
NO20044763L (no) 1-(aminoalkyl)-3-sulfonylazaindoler som 5-hydroksytryptamin-6 ligander
YU98003A (sh) Supstituisana sulfonamidna jedinjenja, postupak za njihovu upotrebu kao leka za tretiranje poremećaja cns, gojaznosti i dijabetesa tipa ii
NO20050828L (no) lndol-3-svovelderivater
AU2804400A (en) Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists
NO20055649L (no) Substituert dihydrokinazolin med antiviale egenskaper
NO20076638L (no) Nye 8-sulfonylamino-3-aminosubstituerte kroman- eller tetrahydronaftalenderivater som modulerer 5HT6-reseptoren
NO20062983L (no) Sulfonamid-derivater for behandling av sykdommer
WO2003028641A3 (en) Mch receptor antagonists
NO20082496L (no) Pyrazinderivater
NO972091L (no) Bestemte substituerte benzylaminderivater; en ny klasse nouropeptid-yl-spesifikke ligander
CA2443724A1 (en) Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
NO20055680L (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
NO20076515L (no) Hydantoinforbindelser
NO20071222L (no) Benzamidforbindelser.
HK1105200A1 (en) Materials and methods for treating coagulation disorders
NO20051503L (no) Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.
NO20032841L (no) Heterocykloindol- eller azaindol-forbindelser som 5- hydroksytryptamin-6-ligander
NO20060718L (no) Substituerte tiofoner og deres anvendelse
NO20080354L (no) Benzofuranylderivater som 5-HT6-reseptorinhibitorer
SE0303480D0 (sv) Benzofuranes

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application